Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy

Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results

(2018) Jerzy P. Szaflarski et al.   EPILEPSIA

Open-label use of Highly* purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes

(2018) Orrin Devinsky et al.   EPILEPSY & BEHAVIOR

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

(2018) Orrin Devinsky et al.   NEUROLOGY

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cannabis for the Treatment of Epilepsy: an Update

(2018) Tyler E. Gaston et al.   Current Neurology and Neuroscience Reports

Inhibitory effects of cannabidiol on voltage-dependent sodium currents

(2018) Mohammad-Reza Ghovanloo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US

(2018) Tristan T. Sands et al.   CNS DRUGS

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

(2018) Lesley Taylor et al.   CNS DRUGS

Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels

(2017) Luciano R. Vilela et al.   EPILEPSY & BEHAVIOR

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Medical Cannabinoids in Children and Adolescents: A Systematic Review

(2017) Shane Shucheng Wong et al.   PEDIATRICS

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

(2016) Orrin Devinsky et al.   LANCET NEUROLOGY

CBD-enriched medical cannabis for intractable pediatric epilepsy

(2016) Michal Tzadok et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

(2015) Alexandra L. Geffrey et al.   EPILEPSIA

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

(2014) Orrin Devinsky et al.   EPILEPSIA

Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19

(2013) Rongrong Jiang et al.   Drug Metabolism and Pharmacokinetics

Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes

(2013) Tracy Glauser et al.   EPILEPSIA

A National Profile of Childhood Epilepsy and Seizure Disorder

(2012) S. A. Russ et al.   PEDIATRICS

Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety

(2011) Satoshi Yamaori et al.   LIFE SCIENCES

Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol

(2008) Hamish Redmond Ross et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

(2007) A Thomas et al.   BRITISH JOURNAL OF PHARMACOLOGY